Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;58(8):3938-3952.
doi: 10.1007/s12035-021-02391-0. Epub 2021 Apr 22.

ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene

Affiliations
Review

ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene

Ana Cazurro-Gutiérrez et al. Mol Neurobiol. 2021 Aug.

Abstract

Myoclonus-dystonia (MD) is a rare childhood-onset movement disorder, with an estimated prevalence of about 2 per 1,000,.000 in Europe, characterized by myoclonic jerks in combination with focal or segmental dystonia. Pathogenic variants in the gene encoding ε-sarcoglycan (SGCE), a maternally imprinted gene, are the most frequent genetic cause of MD. To date, the exact role of ε-sarcoglycan and the pathogenic mechanisms that lead to MD are still unknown. However, there are more than 40 reported isoforms of human ε-sarcoglycan, pointing to a complex biology of this protein. Additionally, some of these are brain-specific isoforms, which may suggest an important role within the central nervous system. In the present review, we aim to provide an overview of the current state of knowledge of ε-sarcoglycan. We will focus on the genetic landscape of SGCE and the presence and plausible role of ε-sarcoglycan in the brain. Finally, we discuss the importance of the brain-specific isoforms and hypothesize that SGCE may play essential roles in normal synaptic functioning and their alteration will be strongly related to MD.

Keywords: Epsilon-sarcoglycan; Isoform; Myoclonus-dystonia; PDZ-motif; Synapse.

PubMed Disclaimer

References

    1. Asmus F, Gasser T (2010) Dystonia-plus syndromes. Eur J Neurol 17(Suppl 1):37–45. https://doi.org/10.1111/j.1468-1331.2010.03049.x - DOI - PubMed
    1. Roze E, Lang AE, Vidailhet M (2018) Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. Curr Opin Neurol 31:484–490. https://doi.org/10.1097/WCO.0000000000000577 - DOI - PubMed
    1. Nardocci N, Zorzi G, Barzaghi C, Zibordi F, Ciano C, Ghezzi D, Garavaglia B (2008) Myoclonus-dystonia syndrome: clinical presentation, disease course, and genetic features in 11 families. Mov Disord 23:28–34. https://doi.org/10.1002/mds.21715 - DOI - PubMed
    1. Timmers ER, Smit M, Kuiper A, Bartels AL, van der Veen S, van der Stouwe AMM, Santens P, Bergmans B et al (2019) Myoclonus-dystonia: distinctive motor and non-motor phenotype from other dystonia syndromes. Parkinsonism Relat Disord 69:85–90. https://doi.org/10.1016/j.parkreldis.2019.10.015 - DOI - PubMed
    1. Wang X, Yu X (2021) Deep brain stimulation for myoclonus dystonia syndrome: a meta-analysis with individual patient data. Neurosurg Rev 44:451–462. https://doi.org/10.1007/s10143-019-01233-x - DOI - PubMed

Supplementary concepts

LinkOut - more resources